Endocrinology

Despite the increasing push for using HCV-positive organs to expand the donor pool, hundreds of livers allografts from donors are still not being used in transplantation.

Diabetic retinopathy (DR) is the most common microvascular complication of diabetes, affecting more than two in five Americans with diabetes.

A resident from Penn State Hershey Medical Center offers perspective on the idea of using SGLT2 inhibitors for primary prevention in patients with type 2 diabetes.

There is concern over whether or not patients are adhering to their treatment during the pandemic.

Results from a randomized trial suggest engaging in an exercise program following weight loss surgery could help protect against bone loss.

Dr. Gerald Shulman discusses how diabetes can eventually be reversed.

An analysis of more than 29k women from two medical centers in California is offering further insight into the effects of discontinuing bisphosphonate treatment in aging women.

By addressing insulin resistance, researchers believe they can reduce the comorbidities associated with type 2 diabetes.

Dr. Giorgino discusses how combining SGLT2 Inhibitors and GLP-1RA could be combined for treating type 2 diabetes.

A 600-patient trial suggests increased vitamin D supplementation was not associated with a decreased risk of falls but could increase risk of severe falls and fall-related injuries.

Check out our latest case report. This report features a man in his 60s presenting to the ED complaining of vomiting a pulsating left-sided headache.

Diabetic patients are more susceptible to severe COVID-19 outcomes.

A digital health program may be effective for patients with diabetes or prediabetes.

An analysis of data over a 12-year period details the disparities in outcomes following first heart attack among female versus male patients.

Patients with normal eGFR increased from 60% at baseline to 80% at 3 years following procedure.

Analysis of 7-year follow-up data from an observational study of severely obese patients details the effects of gastric bypass and gastric banding on long-term diabetes remission.

The TMIOA Medical Director highlights the best sessions, new topics, and growing discussion around the 18th annual congress.

Intervention participants had significant reductions in weight and HbA1c but there were no differences in hospital admissions or health care spending.

An analysis of the Look AHEAD study by investigators at Johns Hopkins details associations between long-term variability of glycemic markers and increased risk of all-cause and cardiovascular mortality.

Pediatric patients who initiated insulin pump therapy within 6 months of diagnosis demonstrated better cardiovascular risk profiles than those who delayed treatment.

Check out this month's Image IQ from VisualDx. This month's quiz features a 62-year-old patient with type 2 diabetes and a persistent rash that was originally diagnosed as eczema.

Our latest case report features a man in his 30s presenting with vomiting, generalized abdominal pain, and tenesmus. Can you determine the correct diagnosis?

An analysis of data from more than 25k women suggests greater adherence to a Mediterranean diet was linked to a lower risk of developing diabetes.

An analysis of data from the Women's Health Initiative suggests spending more than 6.5 hours engaged in sedentary behaviors each day was linked to a 42% increase in risk of heart failure in older women.

Literature is scarce in identifying and characterizing risk of post-operative diabetes mellitus among patients with pancreatic cystic lesions.

In this 3-part feature series, an endocrinologist, a cardiologist, and an internist tackle the topic of who should be in charge of treating patients with diabetes and whether the creation of a cardiometabolic specialty is a worthwhile endeavor.

In the last of our 3-part series examining the idea of a cardiometabolic subspecialty, Simon Murray, MD, offers his thoughts on who should be treating patients with type 2 diabetes.

More studies are planned testing the impact of finerenone.

Finerenone could be another option to SGLT2 inhibitors for this patient population.

Researchers present new data from the SUSTAIN 6 and PIONEER 6 trials during the virtual AHA 2020 conference.